Abstract
BackgroundRituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B cell depletion, with a progressive reduction...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have